Literature DB >> 6283635

Immunotherapy of metastases enhances subsequent chemotherapy.

M G Hanna, M E Key.   

Abstract

In many multimodal therapies of cancer, postsurgical chemotherapy is administered before immunotherapy for treatment of micrometastatic disease. This sequence may not be the most efficacious. Experiments in which strain 2 guinea pigs bearing syngeneic L10 hepatocarcinomas were given immunotherapy showed that infiltrating immune effector cells not only were tumoricidal but disrupted the characteristically compact structure of metastatic foci. When cytotoxic drugs were administered at the peak of this inflammatory response, the survival rate of the guinea pigs increased significantly. We conclude that postsurgical immunotherapy can enhance the effect of cytotoxic drugs administered subsequently.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6283635     DOI: 10.1126/science.6283635

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  5 in total

1.  Increased efficiency of immunotherapy using irradiated tumor cells.

Authors:  J M Wu; J Fitzgerald; S Sonis; T Ravikumar; R Wilson
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

Review 2.  Immunology of metastasis. Can the immune response cope with disseminated tumor?

Authors:  P Frost; R S Kerbel
Journal:  Cancer Metastasis Rev       Date:  1983       Impact factor: 9.264

3.  Adjuvant treatment of locally advanced renal cancer with autologous virus-modified tumor vaccines.

Authors:  H H Kirchner; P Anton; J Atzpodien
Journal:  World J Urol       Date:  1995       Impact factor: 4.226

4.  A randomized phase II study of SRL172 (Mycobacterium vaccae) combined with chemotherapy in patients with advanced inoperable non-small-cell lung cancer and mesothelioma.

Authors:  M E O'Brien; A Saini; I E Smith; A Webb; K Gregory; R Mendes; C Ryan; K Priest; K V Bromelow; R D Palmer; N Tuckwell; D A Kennard; B E Souberbielle
Journal:  Br J Cancer       Date:  2000-10       Impact factor: 7.640

5.  A phase II study of active specific immunotherapy and 5-FU/Leucovorin as adjuvant therapy for stage III colon carcinoma.

Authors:  A Baars; A M E Claessen; J Wagstaff; G Giaccone; R J Scheper; S Meijer; M J A G Schakel; H E Gall; C J L M Meijer; J B Vermorken; H M Pinedo; A J M van den Eertwegh
Journal:  Br J Cancer       Date:  2002-04-22       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.